Prior auth implied for repeat in‑lab PSG used for PAP titration or efficacy assessment

Prior authorization is implied for repeat in‑lab polysomnography when used to initiate or titrate PAP therapy or to assess efficacy of surgery/devices; ensure requests reference the PSG indications and AHI/RDI thresholds that justify repeat testing.

• Repeat in‑lab PSG covered to initiate/titrate PAP in adults with AHI/RDI ≥15 events/hr or AHI/RDI ≥5 with OSA signs/symptoms, and in children with pediatric thresholds (AHI/RDI ≥5 or ≥1.5 with symptoms).
• Split‑night option may be used when moderate‑to‑severe OSA is documented in first portion to avoid a second study.

Verify product-specific benefits and applicability

Check member product and program benefits before ordering or billing—this policy applies only to certain Capital Blue Cross programs and products and benefit variations (e.g., FEP PPO) may change coverage and prior authorization requirements.

• Refer to the member's product-specific benefit documents (FEP PPO refers to the FEP Medical Policy Manual) for applicability.
• Verify eligibility and benefit terms on the date of service.

Document medical necessity for listed CPT/HCPCS codes

Document and demonstrate medical necessity for listed CPT/HCPCS codes; coverage is determined by member benefit information and eligibility and codes such as G0400, 95801, 95806–95811, G0398, and G0399 are covered only when medically necessary.

• Include clinical indication, pertinent signs/symptoms, and where applicable AHI/RDI values that meet policy thresholds.
• Confirm member eligibility and benefit limitations prior to testing.

Use split‑night study when moderate‑to‑severe OSA documented to avoid second study

When diagnostic PSG documents moderate‑to‑severe OSA in the initial portion of a study, document that finding clearly to permit a split‑night study (diagnostic then PAP titration) and avoid an additional titration study.

• Record the documented AHI/RDI severity in the first portion of the study and the time period used to establish it.
• Use split‑night only when criteria (moderate‑to‑severe OSA documented in first portion) are met per policy guidance.

Treat OSA before ordering MSLT for narcolepsy evaluation

Treat identified obstructive sleep apnea before performing a Multiple Sleep Latency Test (MSLT) to confirm narcolepsy; address and document OSA treatment because OSA‑related sleepiness can confound MSLT results.

• Document that OSA was identified and treated (or treatment attempted) prior to ordering MSLT for narcolepsy evaluation.
• Note that MSLT is not routinely indicated for OSA evaluation or post‑CPAP assessment.

Use positive multi‑channel portable study (O2 sat, airflow, effort) as basis for CPAP trial

A positive portable monitoring (home) study that includes arterial oxygen saturation, airflow, and respiratory effort can be used as the basis for a CPAP trial to determine treatment efficacy; document the device channels used and the positive result.

• Ensure the portable study included sensors for oxygen saturation, airflow, and respiratory effort (or validated alternatives) before using it to justify a CPAP trial.
• If the portable test is negative or the patient fails CPAP, further evaluation (e.g., in‑lab PSG) is required.

Physician‑review of test summary and raw data required (specialist training)

Have test summaries and raw data reviewed by a physician trained in sleep medicine; interpreters should review raw PSG and HSAT data to detect artifacts and data loss and include this review in the record.

• Include in the report a statement that a sleep‑medicine‑trained physician reviewed the test summary and raw data.
• Document any data loss, artifacts, or technical issues noted during review.

Ensure raw‑data review and device channel requirements are met (recommend 4 channels)

Review raw device data and ensure home/portable monitoring devices provide recommended channels—current recommendations favor devices with at least 4 channels (oxygen saturation, respiratory effort, airflow, heart rate) and permit raw data review; type 4 monitors with fewer than 3 channels are not recommended.

• Confirm the device provides required sensors (respiratory effort, airflow, oxygen saturation) or validated equivalent (e.g., PAT + oximetry + actigraphy).
• Retain and document raw data review performed by a trained professional.

Document coding and medical necessity; verify member benefits/eligibility

Document coding, clinical indications, and medical necessity for each test; coverage is determined by member benefits and eligibility on the date of service so verify and record benefit details.

• Include the clinical rationale, relevant AHI/RDI values, and product‑specific benefit applicability in the request or claim.
• Verify and record member eligibility and benefit terms prior to testing.

Avoid home (unattended) testing when conditions may alter ventilation or in children — risk of denial

Do not order or rely on unattended home sleep studies for patients with health conditions that might alter ventilation (e.g., central sleep apnea, heart failure, chronic pulmonary disease, obesity hypoventilation syndrome, neuromuscular disorders with sleep‑related symptoms, injurious parasomnias, or narcolepsy) or for children; such home testing is considered investigational and may be denied.

• If such conditions are present, plan supervised in‑lab PSG and document the contraindicating condition in the record.
• Unattended home studies are investigational in patients <18 years.

Studies not meeting PSG criteria or AHI/RDI thresholds risk denial

Ensure supervised and unattended home sleep studies meet the policy's in‑lab PSG criteria and AHI/RDI thresholds; studies that do not meet these criteria (including insufficient AHI/RDI for PAP titration) are considered investigational and may be denied.

• For PAP titration justification, document AHI/RDI ≥15 in adults or ≥5 with symptoms (adult) per policy, or pediatric thresholds where applicable.
• If a home or supervised study fails to meet stated criteria, obtain in‑lab PSG and document justification for repeat testing.

MSLT/MWT not indicated for routine OSA evaluation—risk of denial if used in that context

Do not use the MSLT or MWT for routine OSA evaluation or for assessing change after CPAP; ordering these tests in that context risks denial—the MSLT is reserved for narcolepsy evaluation and only after OSA has been treated.

• Treat and document management of OSA prior to MSLT when evaluating suspected narcolepsy.
• Avoid using MSLT/MWT to evaluate OSA severity or post‑CPAP response.

Investigational code 94799 is not covered — billing/claim denial risk

Do not bill or submit claims using investigational procedure code 94799 for these services; procedure code 94799 is listed as investigational and not covered and claims with this code may be denied.

• Use the appropriate covered CPT/HCPCS codes (e.g., G0400, 95801, 95806–95811, G0398, G0399) when medically necessary and supported by documentation.
• If an investigational code is submitted, expect claim denial.